pyrroles and spd 502
pyrroles has been researched along with spd 502 in 9 studies
Research
Studies (9)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Drejer, J; Gouliaev, AH; Jensen, LH; Mathiesen, C; Moller, A; Nielsen, EO; Varming, T; Wätjen, F | 1 |
| Dewar, D; Fowler, JH; McCracken, E; McCulloch, J; Morrison, S | 1 |
| Blackburn-Munro, G; Bomholt, SF; Erichsen, HK | 1 |
| Gajhede, M; Greenwood, JR; Kasper, C; Kastrup, JS; Kristensen, AS; Liljefors, T; Mirza, O; Olsen, L; Pickering, DS; Schousboe, A; Sigurskjold, BW; Wätjen, F | 1 |
| Mathiesen, C; Møller, A; Nissinen, J; Pitkänen, A; Rønn, LC | 1 |
| Almqvist, PM; Finnerup, NB; Gormsen, L; Jensen, TS | 1 |
| Perucca, E | 1 |
| Ben-Menachem, E; Møller, A; Rysgaard, K; Sabers, A; Wolf, P | 1 |
| Keppel Hesselink, JM | 1 |
Reviews
1 review(s) available for pyrroles and spd 502
| Article | Year |
|---|---|
What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate.
Topics: Acetamides; Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Fructose; Humans; Lacosamide; Pyrroles; Pyrrolidinones; Rats; Receptors, AMPA; Status Epilepticus; Tetrahydroisoquinolines; Topiramate; Treatment Outcome | 2009 |
Trials
2 trial(s) available for pyrroles and spd 502
| Article | Year |
|---|---|
The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study.
Topics: Adult; Aged; Analgesia; Anesthetics, Local; Chronic Disease; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Hyperalgesia; Infusions, Intravenous; Lidocaine; Male; Middle Aged; Neuralgia; Pain Measurement; Peripheral Nerve Injuries; Peripheral Nerves; Peripheral Nervous System Diseases; Pyrroles; Receptors, AMPA; Receptors, Kainic Acid; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Young Adult | 2009 |
A prospective, randomized, multicentre trial for the treatment of refractory status epilepticus; experiences from evaluating the effect of the novel drug candidate, NS1209.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials, Phase II as Topic; Drug Resistance; Endpoint Determination; Female; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Receptors, AMPA; Research Design; Status Epilepticus; Tetrahydroisoquinolines; Treatment Outcome | 2013 |
Other Studies
6 other study(ies) available for pyrroles and spd 502
| Article | Year |
|---|---|
SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Binding Sites; Binding, Competitive; Cell Membrane; Cells, Cultured; Cerebral Cortex; Electroshock; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glycine; Isoquinolines; Kainic Acid; Kinetics; Male; Membrane Potentials; Mice; Mice, Inbred Strains; Molecular Structure; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Pipecolic Acids; Pyrroles; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Seizures; Stereoisomerism; Tetrahydroisoquinolines | 1999 |
Grey matter and white matter ischemic damage is reduced by the competitive AMPA receptor antagonist, SPD 502.
Topics: Aldehydes; Animals; Brain Ischemia; Carotid Artery, External; Carotid Artery, Internal; Disease Models, Animal; Functional Laterality; Growth Inhibitors; Humans; Isoquinolines; Male; Oligodendroglia; Periaqueductal Gray; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Tetrahydroisoquinolines | 2002 |
Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Excitatory Amino Acid Antagonists; Male; Morphine; Narcotics; Pain; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Pyrroles; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Kainic Acid; Tetrahydroisoquinolines; Time Factors | 2004 |
The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Dimerization; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Hydrogen Bonding; Macromolecular Substances; Models, Molecular; Molecular Structure; Protein Structure, Quaternary; Pyrroles; Quinoxalines; Rats; Receptors, AMPA; Recombinant Proteins; Tetrahydroisoquinolines; Thermodynamics | 2006 |
Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat.
Topics: Amygdala; Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Hippocampus; Kainic Acid; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Status Epilepticus; Tetrahydroisoquinolines; Video Recording | 2007 |
NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Epilepsy; Humans; Neuralgia; Pyrroles; Receptors, AMPA; Stroke; Tetrahydroisoquinolines; Treatment Outcome | 2017 |